Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Case Report Volume 5 Issue 11

A Unique Case of Isolated Dehydroepiandrosterone-Sulfate Secreting Adrenocortical Carcinoma: A Case Report with Review of the Literature

Vijaya Ganta, MD*; Gail Nunlee-Bland, MD; and Terrence Fullum, MD

Division of Endocrinology, Diabetes and Metabolism, Howard University Hospital, NW Washington, USA

*Corresponding Author: Vijaya Ganta, MD, Division of Endocrinology, Diabetes and Metabolism, Howard University Hospital, NW Washington, USA.

Received: September 25, 2021; Published: October 19, 2021



Objective: Our objective is to report a case of isolated dehydroepiandrosterone-sulfate (DHEA-S) secreting adrenocortical carcinoma.

Case Presentation: A 52-year-old African American woman with a medical history of asthma for more than 10 years presented with shortness of breath, chest tightness, and cough. A diagnosis of acute asthma exacerbation with pleuritic chest pain was made, and a CT scan of the chest revealed an incidental left adrenal mass. The patient denied hyperandrogenic symptoms like deepening of the voice, acne, and excessive hair growth. The physical examination was normal, and there was no clitoromegaly. The endocrine workup was significant for increased DHEA-S 766 mcg/dl (15-170 mcg/dl), and the repeat DHEA-S was 829 mcg/dl. All other adrenal hormone levels were within normal limits. The CT scan of the abdomen and pelvis without contrast revealed a 5.5 cm left adrenal mass with Hounsfield units of 23. An open left adrenalectomy was done. Histopathology was reported as marked and diffuse nuclear atypia, necrosis, and atypical mitotic figures. The tumor was strongly positive for inhibin, synaptophysin, and melan-A. The Ki-67 immunostain showed 20-25% positive staining.

Discussion: Adrenocortical carcinoma (ACC) is a rare adrenal cortex malignancy. Both size more than 4 cm and radiographic appearance are significant predictors of malignancy. An isolated DHEA-S secreting ACC patient may have a DHEA-S level more than 3 times the normal upper limit.

Conclusion: Isolated DHEA-S secreting adrenocortical carcinoma patients may present without hyperandrogenic features like hirsutism and virilization.



  1. Bodie B., et al. “The Cleveland Clinic experience with adrenal cortical carcinoma”. The Journal of Urology2 (1989): 257-260.
  2. Wajchenberg Bernardon Leo., et al. “Adrenocortical carcinoma”. Cancer4 (2000): 711-736.
  3. Luton Jean-Pierre., et al. “Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy”. New England Journal of Medicine17 (1990): 1195-1201.
  4. Allolio Bruno and Martin Fassnacht. “Adrenocortical carcinoma: clinical update”. Journal of Clinical Endocrinology and Metabolism 6 (2006): 2027-2037.
  5. Fassnacht Martin and Bruno Allolio. “Clinical management of adrenocortical carcinoma”. Best Practice and Research Clinical Endocrinology and Metabolism2 (2009): 273-289.
  6. Ng Linda and John M Libertino. “Adrenocortical carcinoma: diagnosis, evaluation and treatment”. The Journal of Urology1 (2003): 5-11.
  7. Young Jr and William F. “Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota”. Endocrinology and metabolism clinics of North America1 (2000): 159-185.
  8. Angeli A., et al. “Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group”. Hormone Research in Paediatrics4-6 (1997): 279-283.
  9. Grumbach MM., et al. “Management of the clinically inapparent adrenal mass (“incidentaloma”)”. Annals of Internal Medicine 138 (2003): 424-429.
  10. Balasubramanian Sanjeeve and Tito Fojo. “Practical considerations in the evaluation and management of adrenocortical cancer”. Seminars in Oncology 6 (2010): 619-626.
  11. Veytsman Irina., et al. “Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma”. Journal of Clinical Oncology27 (2009): 4619-4629.
  12. Fassnacht M., et al. “Adrenal tumors: how to establish malignancy?”. Journal of Endocrinological Investigation4 (2004): 387-399.
  13. Stojadinovic Alexander., et al. “Adrenocortical carcinoma: clinical, morphologic, and molecular characterization”. Journal of Clinical Oncology4 (2002): 941-950.
  14. Wachenfeld Christoph., et al. “Discerning malignancy in adrenocortical tumors: are molecular markers useful?” European Journal of Endocrinology3 (2001): 335-341.


Citation: Vijaya Ganta, MD., et al.. “A Unique Case of Isolated Dehydroepiandrosterone-Sulfate Secreting Adrenocortical Carcinoma: A Case Report with Review of the Literature”.Acta Scientific Medical Sciences 5.11 (2021): 81-85.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US